Propranolol for severe hemangiomas of infancy.
- C. Léauté-Labrèze, E. Dumas de la Roque, T. Hubiche, F. Boralevi, J. Thambo, A. Taïeb
- MedicineNew England Journal of Medicine
- 12 June 2008
It is observed in 11 children that propranolol can inhibit the growth of infantile capillary hemangiomas and this work is hopeful that this discovery will help improve the prognosis of these patients.
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic.
- T. Hubiche, N. Cardot-Leccia, T. Passeron
- MedicineJAMA dermatology
- 25 November 2020
The results suggest that chilblain-like lesions observed during the COVID-19 pandemic represent manifestations of a viral-induced type I interferonopathy.
Clinical Phenotype of Scabies by Age
- F. Boralevi, A. Diallo, K. Ezzedine
- MedicinePediatrics
- 1 April 2014
There is a specific clinical presentation of scabies in infants and children that seems to vary according to age, taking into account these specificities may be helpful for the early diagnosis and the identification of cases to prevent the propagation of the disease.
Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort.
- T. Hubiche, C. Ged, F. Boralevi
- BiologyActa Dermato-Venereologica
- 2007
The association of atopic dermatitis with filaggrin variants was confirmed, but not that of SPINK5 or KLK7 polymorphisms, which may modulate systemic immune effects favouring the IgE response to atopens.
Dermatological Spectrum of Hand, Foot and Mouth Disease from Classical to Generalized Exanthema
- T. Hubiche, I. Schuffenecker, P. Del giudice
- MedicineThe Pediatric Infectious Disease Journal
- 1 April 2014
Hospitalised children with confirmed HFMD have a clinical spectrum ranging from classical to generalized vesicular exanthema, and CV-A6 is associated with peri-oral rash, which is related to coxsackie virus A6 when there is an atypical rash.
Skin manifestations of COVID‐19 in children: Part 1
- D. Andina, A. Belloni-Fortina, A. Torrelo
- MedicineClincal and Experimental Dermatology
- 12 November 2020
This review summarizes the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe.
Anti‐PD1‐induced psoriasis: a study of 21 patients
- J. Bonigen, C. Raynaud-Donzel, E. Mahé
- Medicine, BiologyJournal of the European Academy of Dermatology…
- 1 May 2017
Nivolumab is licensed in advanced melanoma and second-line therapy of advanced or metastatic non-small cell lung cancer, and pembrolizumab (Keytruda®), atezolIZumab, and pidilizumABab are anti-PD1 monoclonal antibodies.
Epicutaneous aeroallergen sensitization in atopic dermatitis infants – determining the role of epidermal barrier impairment
- F. Boralevi, T. Hubiche, A. Taïeb
- MedicineAllergy. European Journal of Allergy and Clinical…
- 1 February 2008
This work has shown that early epidermal barrier impairment may facilitate the epicutaneous penetration of atopens.
Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection
- N. Cardot-Leccia, T. Hubiche, J. Dellamonica, F. Burel-Vandenbos, T. Passeron
- MedicineIntensive Care Medicine
- 12 June 2020
Skin manifestations of COVID‐19 in children: Part 2
- D. Andina, A. Belloni-Fortina, A. Torrelo
- MedicineClincal and Experimental Dermatology
- 9 November 2020
This review summarizes the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe.
...
...